Back to All Combinations
TMB-High + MSS
Intermediate PrognosisGenes Involved
TMB-High
MSS
Recommended Treatments
Pembrolizumab (FDA approved for TMB-H)
Consider combination immunotherapy
Treatments to Avoid
No specific contraindications noted
Key Statistics
3.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
TMB-H tumors may respond to immunotherapy even if MSS. Pembrolizumab has tumor-agnostic approval.
Information
Category: General
Evidence Level: B
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.